Lisata Acquires Marea Therapeutics And Secures $225M Financing To Advance Next-Generation Medicines For Cardioendocrine Diseases
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseasesMarea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG)
Lisata bought another medicine company called Marea. They got $225 million to pay for it. Now they are working together to make new heart and hormone medicines. When companies join up and get big money, watch if their new medicines work well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.